Top Markets
Coin of the day
CinCor Pharma, Inc. CinCor Pharma, Inc.

CinCor Pharma, Inc.

CINC
Rangering i aksjer #11594
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical... CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldosteronism, and various other cardio-renal disorders. Additionally, CIN-107 is in Phase I clinical evaluation for its potential in treating chronic kidney diseases. The company holds a significant licensing agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. Established in 2018, CinCor Pharma, Inc. maintains its principal operations in Boston, Massachusetts.
Aksjekurs
$29.06
Sist synkronisert: 2023-02-23
Markedsverdi
$682.73M
Endring (1 dag)
-0.48%
Endring (1 år)
0.00%
Land
US
Handel CinCor Pharma, Inc. (CINC)

Kategori

P/S-forhold for CinCor Pharma, Inc. (CINC)
P/S-forhold per 2026 TTM: 0
Ifølge CinCor Pharma, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for CinCor Pharma, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH